Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

Completed · Phase 3 · Has a placebo group

Conditions studied: Endometrial Hyperplasia, Osteoporosis

In brief

The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.

Key facts

Study ID

NCT00242710

Run by

Pfizer

People needed

1083

Starts

2005-09-01

Expected to finish

2008-09-01

Last updated by the study team

2013-12-20

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Generally healthy, postmenopausal women, aged 40 to less than 65 years
• Intact uterus
• At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels > 40 mIU/mL.

You may not qualify if…

• Use of oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening (12 weeks for the osteoporosis substudy)
• A history or active presence of clinically important medical disease
• Malabsorption disorders

Where it is running

• Pfizer Investigational Site — Upland, California, United States
• Pfizer Investigational Site — Inverness, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Decatur, Georgia, United States
• Pfizer Investigational Site — Honolulu, Hawaii, United States
• Pfizer Investigational Site — Lexington, Kentucky, United States
• Pfizer Investigational Site — Billings, Montana, United States
• Pfizer Investigational Site — Eugene, Oregon, United States
• Pfizer Investigational Site — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.